Li Jia

14PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular medicinePredictive and prognostic markersMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 17, 2026
A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.

|Dec 17, 2025
cGAS restricts PARP1-mediated microhomology-mediated end joining by suppressing poly-ADP-ribosylation.

Haibo Yang, Boya Gao, Bo Wu

|Sep 26, 2025
Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer.

Lin Wang, Brian R Sardella, Abhishek Thavamani

|Sep 26, 2025
Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.

Filipe Lf Carvalho, Jihyun Lee, Nikolaos Kalavros

|Apr 23, 2025
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer.

Fu Gui, Baishan Jiang, Jie Jiang

|Jul 19, 2024
Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer.

Fu Gui, Baishan Jiang, Jie Jiang

Pageof 3

Frequent Collaborators

4 joint publications

Fu Gui

3 joint publications

Takuya Tsujino

2 joint publications

Takeshi Tsutsumi

2 joint publications

Zoltan Szallasi